Anti-CD19 chimeric antigen receptor T cell therapy - Cellular Biomedicine Group

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Cellular Biomedicine Group

Alternative Names: Anti-CD19 CART cell therapy - Cellular Biomedicine Group; Anti-CD19 CART cells; C-CAR011; CD19 specific CART cells

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chinese PLA General Hospital
  • Developer Cellular Biomedicine Group; Chinese PLA General Hospital
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma; Follicular lymphoma; Leukaemia; Mantle-cell lymphoma
  • Phase I Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 31 Oct 2017 Cellular Biomedicine and Peking University People's Hospital plan a clinical trial for Acute lymphoblastic leukaemia (In adolescents, In adults) in China (NCT03327285)
  • 03 Oct 2017 Cellular Biomedicine in collaboration with Tianjin Medical University Cancer Institute and Hospital plans a phase I trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) (NCT03299738)
  • 03 May 2017 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (IV) (NCT03154775)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top